ClinicalTrials.gg
Not yet recruitingNCT07950059PUMCH-1-YSYUpdated Nov 20, 2026

Effects of Inulin-Based Prebiotics on Gut Microbiota After Rectal Cancer Surgery

An interventional study of Inulin-Based Compound Prebiotics and Compound Lactobacillus Enteric-Coated Capsules in Rectal Cancer Patients and Gut Microbiota Dysbiosis, sponsored by Peking Union Medical College Hospital. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital — 9 open to participants now, 10 under way, none of them phase 3. Rectal Neoplasms · Peking Union Medical College Hospital.

Planned enrollment
3rd of 11
261 · median 150
Started
2026
with 1 other
No phase
7 of 13
5 open now
Registered
13th of 13
by date

Among the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 13th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

9 of the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

Postoperative gut microbiota dysbiosis is a common clinical concern in patients undergoing rectal cancer surgery and may contribute to gastrointestinal dysfunction and postoperative complications. Inulin-based compound prebiotics may help maintain intestinal microbial balance by promoting beneficial bacteria and modulating gut microbial composition. However, their efficacy and safety in preventing postoperative gut microbiota dysbiosis in patients with rectal cancer remain to be established.

This study is a multicenter, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to evaluate the efficacy and safety of inulin-based compound prebiotics in preventing gut microbiota dysbiosis following radical rectal cancer surgery and to assess their effects on gut microbiota composition.

A total of 261 adult patients with histologically confirmed rectal adenocarcinoma undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma will be enrolled at three study centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) inulin-based compound prebiotics combined with probiotics, (2) probiotics combined with placebo, or (3) placebo alone. Study interventions will be administered from postoperative day 1 through day 5.

The primary outcome is the incidence of gut microbiota dysbiosis within five days after surgery. Secondary outcomes include changes in gut microbiota composition and diversity, inflammatory markers, and fecal short-chain fatty acid levels. Gut microbiota will be assessed using 16S rRNA gene sequencing and metagenomic sequencing. Safety will be evaluated through the monitoring and recording of adverse events throughout the intervention period.

This study aims to provide clinical evidence regarding the efficacy and safety of inulin-based compound prebiotics for preventing postoperative gut microbiota dysbiosis and their potential role in modulating intestinal microbial homeostasis in patients undergoing rectal cancer surgery.

03

Conditions studied

  • Rectal Cancer Patients
  • Gut Microbiota Dysbiosis

Keywords

  • Rectal Cancer
  • Inulin
  • Prebiotics
  • Probiotics
  • Gut Microbiota
  • Postoperative Complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. (ECOG) performance status of 0-3 before surgery.
  3. confirmed rectal adenocarcinoma diagnosed by endoscopic , with the lower margin of the tumor located ≤12 cm from the anal verge.
  4. Undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma.
  5. Willing and able to provide written , understand and comply with study requirements and procedures, and not currently participating in another clinical study considered by the investigator to conflict with this study.

Exclusion criteria

Exclusion Criteria:

  1. Known intolerance to inulin or prebiotics.
  2. History of severe irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
  3. Presence of distant , including liver or lung metastases.
  4. Severe intestinal obstruction, gastrointestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency treatment.
  5. Undergoing open radical rectal cancer surgery or conversion from laparoscopic to open surgery.
  6. Use of antibiotics (excluding planned perioperative antibiotic prophylaxis), prebiotics, probiotics, synbiotic products, or agents within one month before surgery.
  7. Severe cardiovascular, cerebrovascular, hepatic, renal, pulmonary, or hematopoietic system diseases.
  8. Pregnant or breastfeeding women.
  9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
261 participants (estimated)

Study arms

  • Experimental
    Inulin-Based Compound Prebiotics Plus Probiotics

    Participants in this group will receive oral inulin-based compound prebiotics (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), combined with compound Lactobacillus enteric-coated capsules (0.66 g three times daily) and a triple viable Bifidobacterium preparation (0.42 g three times daily). All interventions will be administered from postoperative day 1 through day 5.

    Dietary Supplement: Inulin-Based Compound Prebiotics · Drug: Compound Lactobacillus Enteric-Coated Capsules · Drug: Triple Viable Bifidobacterium Preparation

  • Active comparator
    Probiotics Plus Placebo

    Participants in this group will receive compound Lactobacillus enteric-coated capsules (0.66 g orally three times daily) and a triple viable Bifidobacterium preparation (0.42 g orally three times daily), combined with maltodextrin placebo administered at the same dosage and schedule as the inulin-based compound prebiotics group. All interventions will be administered from postoperative day 1 through day 5.

    Drug: Compound Lactobacillus Enteric-Coated Capsules · Drug: Triple Viable Bifidobacterium Preparation · Drug: Maltodextrin Placebo

  • Placebo comparator
    Placebo

    Participants in this group will receive oral maltodextrin placebo (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), together with additional maltodextrin placebo (0.66 g and 0.42 g, each administered orally three times daily) to match the probiotic preparations used in the other groups. All interventions will be administered from postoperative day 1 through day 5.

    Drug: Maltodextrin Placebo

Interventions

  • Dietary supplementInulin-Based Compound Prebiotics

    An oral inulin-based compound prebiotic supplement containing inulin (62.5%), polydextrose (10%), allulose (10%), isomaltooligosaccharides (7.88%), tagatose (7.75%), hyaluronic acid (1.25%), and chitosan oligosaccharides (0.63%). Participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g orally twice daily on postoperative days 2-5. The intervention will be administered in combination with probiotic preparations in the experimental group.

  • DrugCompound Lactobacillus Enteric-Coated Capsules

    An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

  • DrugTriple Viable Bifidobacterium Preparation

    An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

  • DrugMaltodextrin Placebo

    Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens.

06

What researchers measure

Primary outcomes

  1. Incidence of Postoperative Gut Microbiota Dysbiosis

    The primary outcome is the proportion of participants who develop gut microbiota dysbiosis within five days following laparoscopic radical rectal cancer surgery with a protective intestinal stoma. Postoperative gut microbiota dysbiosis will be assessed based on clinical manifestations, including abdominal distension, diarrhea or increased stoma output, abdominal pain, fever, nausea, and vomiting, together with relevant laboratory findings. The incidence will be calculated as the number of participants diagnosed with postoperative gut microbiota dysbiosis divided by the total number of participants evaluated in each treatment group, expressed as a percentage.

    Time frame: Postoperative days 1-5

Secondary outcomes

  1. Changes in Gut Microbiota Composition and Diversity

    Changes in gut microbiota composition and diversity will be assessed using metagenomic sequencing of fecal samples collected before surgery and during the postoperative period. Gut microbiota composition will be evaluated based on changes in microbial community structure and the relative abundance of bacterial taxa, while microbial diversity will be assessed using diversity indices derived from sequencing data. Changes in gut microbiota composition and diversity will be compared among the three treatment groups.

    Time frame: Preoperatively and on postoperative days 3 and 5

  2. Changes in the Bifidobacterium-to-Escherichia coli Ratio (B/E Ratio)

    The Bifidobacterium-to-Escherichia coli ratio (B/E ratio) in fecal samples will be assessed using gut microbiota sequencing data. Changes in the B/E ratio will be compared among the three treatment groups to evaluate alterations in intestinal microbial balance following surgery.

    Time frame: Preoperatively and on postoperative days 3 and 5

  3. Serum C-Reactive Protein (CRP) Level

    Serum C-reactive protein (CRP) levels will be measured to assess postoperative inflammatory responses. CRP concentrations will be compared among the three treatment groups. Results will be reported in mg/L.

    Time frame: Preoperatively and on postoperative days 3 and 5

  4. Serum Procalcitonin (PCT) Level

    Serum procalcitonin (PCT) levels will be measured as an indicator of postoperative inflammatory responses. PCT concentrations will be compared among the three treatment groups. Results will be reported in ng/mL.

    Time frame: Preoperatively and on postoperative days 3 and 5

  5. Serum Interleukin-6 (IL-6) Level

    Serum interleukin-6 (IL-6) levels will be measured to evaluate postoperative inflammatory responses. IL-6 concentrations will be compared among the three treatment groups. Results will be reported in pg/mL.

    Time frame: Preoperatively and on postoperative days 3 and 5

  6. Fecal Short-Chain Fatty Acid (SCFA) Levels

    Fecal concentrations of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, will be measured to assess gut microbial metabolic activity. Changes in individual SCFA concentrations before and after surgery will be compared among the three treatment groups.

    Time frame: Preoperatively and on postoperative days 3 and 5

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers due to participant privacy and confidentiality considerations and the absence of an approved data-sharing plan.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 13 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 20, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950059
Responsible party
Guole Lin (Chief Physician and Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Guole Lin
Contact
linguole@126.com
010-13001081483

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion